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The 4th Global Forum on TB Vaccines, convened in Shanghai, China, from 21 e 24 April 2015, brought
together a wide and diverse community involved in tuberculosis vaccine research and development to
discuss the current status of, and future directions for this critical effort. This paper summarizes the
sessions on Immunopathogenesis of Tuberculosis, and Immunopathogenesis and Novel Mechanisms of
Vaccine Activity. Summaries of all sessions from the 4th Global Forum are compiled in a special sup-
plement of Tuberculosis. [August 2016, Vol 99, Supp S1, S1eS30].
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Development of effective tuberculosis (TB) vaccines has been
hindered by a general lack of understanding as to the antigens
needed to generate a protective immune response against Myco-
bacterium tuberculosis (Mtb), and by gaps in our knowledge con-
cerning an immune correlate of protection against Mtb infection
and TB disease. Presentations in this section focused on addressing
both of these critical needs.2. TB vaccine antigen selection
Dr. Joel Ernst (NYU Langone Medical Center, USA) addressed the
question of the strategies that could be undertakenwhen attempting
to select antigens for inclusion in TB vaccines. He began his presen-
tation by distinguishing antigens whose mechanisms of protective
immunity aremediated byantibodies or T lymphocytes. Four types of
antibody-mediated protection strategies were discussed: 1)
neutralization e generated by a) toxins capable of stimulating anti-
toxins; b) antigens that stimulate antibodies which neutralize viru-
lence factors; and c) antigens that stimulate antibodies targeting
critical external pathogen molecules involved in target cell attach-
ment and fusion; 2) opsonization resulting from antigens derived
from exposed surface components that are not shed by the targeted
organism; 3) complement mediated lysis e derived from antigensRockville, MD, 20850, USA.
).
Ltd. This is an open access article uthat stimulateantibodies topathogenmembraneassociatedproteins;
and 4) antibody dependent cytotoxicity e mediated by antigens
expressed on the surface of infected cells.
For T-cell mediated responses, the selection of antigens is less
dependent on the actual structural position of the antigens, i.e.,
whether theyare secreted,membrane-boundor intracellular, thanon
their expression at crucial times and locations in the infectious life
cycleof thepathogen. Twocritical compartments forvaccine-induced
T-cell stimulation are 1) the lymph nodes, where naïve T-cells are
presented antigens mainly by dendritic cells (DCs), and 2) the site of
infection where effector T-cells are presented antigens mainly by
infectedmacrophages. T-cell stimulating antigens have epitopes that
are recognized and presented by HLA molecules. There is limited
precedent for T-cell mediated vaccines for humans, however, as only
one licensed vaccine, targeted at preventing herpes zoster, likely
works via cell mediated immunity (CMI). In contrast, all other
licensed vaccines act through antibody-mediated mechanisms.
Ernst spelled out his vision of the minimal requirements for a TB
vaccine. He noted that antigen-presenting cells, mainly DCs, pre-
sent antigen in secondary lymphoid tissue to prime and activate
naïve T-cells. Antigen also is presented to T-cells, however, at the
actual site of infection, mainly by macrophages. To elicit optimal
protection, “memory or effector” T-cells must be located at the site
of infection so they can recognize and quickly respond to Mtb-
infected cells.
Mtb has, on average, 4003 protein antigens, out of which 3975
open reading frames (orfs) contain predicted T-cell epitopes. A total
of 21,882 epitopes are predicted in silico [1] with 1641 of them
having been experimentally veriﬁed. Of these, 680 are non-nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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be recognized by CD4þ or CD8þ T-cells. T-cell responses have been
detected to 512 unique Mtb protein products thus far. Products of
65 orfs induce T-cell responses in 5% of infected but healthy
subjects (about 1.5% of the Mtb proteome) [1].
Multiple differences distinguish the various Mtb antigens and
must be taken into account when considering them for potential
inclusion in a TB vaccine. Some differences include their abun-
dance, their subcellular localization (in the cell wall, cell mem-
brane, cytoplasm), whether or not they are secreted by the bacteria,
the frequency of immune recognition by infected persons (their
“immunodominance”), the regulation of their expression, the na-
ture of their trafﬁcking via vesicles in infected host cells, their as-
sociationwith virulence or virulence loci, and their conservation or
variation in Mtb strains, and between Mtb and non-tuberculous
mycobacteria (NTM).
When discussing antigen selection for TB vaccine development,
another issue to consider is antigen speciﬁcity. Studying BCG, an
attenuated Mycobacterium bovis vaccine, is helpful in this regard,
given that it is the only vaccine as yet found to be efﬁcacious,
though only partially, against any form of TB (mainly disseminated
pediatric TB). BCG strains lack at least 33 genes included in virulent
Mtb [2], representing half of the virulence targets present in Mtb.
All BCG strains contain a mutation in the immunodominant Mtb
antigen, Ag85B that appears to destabilize the protein [2], resulting
in much less secretion of this protein than is found in Mtb strains.
Most antigens found in current Mtb subunit vaccines are
secreted proteins; very few are non-secreted. Many were selected
due to their immunodominance [1]. Mtb secreted antigens are
exported from infected cells, focusing immune responses on un-
infected cells and thereby diminishing responses to infected cells,
thus hindering T-cell control of intracellular Mtb [3]. This repre-
sents a potentially important immune evasion mechanism, given
that T-cells must recognize Mtb-infected cells to generate the full
extent of cell-mediated control [4].
Ernst concluded by noting that most Mtb T-cell epitopes are
hyperconserved, eliciting very little antigenic variation, although
rare Mtb T-cell epitopes have been discovered that do exhibit evi-
dence of selection pressure from human T-cell recognition [5].
Whether these represent the best potential targets for vaccine-
generated immune responses remains an important question in
future TB vaccine development.
3. Cytokine responses to TB: implications for pathogenesis
Dr. Katrin Mayer-Barber (National Institute of Allergy and In-
fectious Diseases, National Institutes of Health, USA) discussed the
role of IL-1 in the control ofMtb infection. During the acute phase of
infection in mice, there is constant increase in Mtb colony-forming
units (CFU) accompanied by an increase in TNF-alpha and IL-1. IL-
1R1 knock out mice show severe necrotic lung pathology following
Mtb infection compared towild typemice, suggesting an important
role for IL-1 in controlling infection. Lipid mediators derived from
arachidonic acid are involved in controlling apoptotic versus
necrotic cell death of infected macrophages, with the latter pro-
moting bacterial spread. IL-1, through the COX-2 axis and produc-
tion of prostaglandin 2 (PGE-2), prevents necrotic cell death and
extracellular release of bacteria, often associated with 5-
lipoxygenase (5-LO) products [6]. IL-1 induces PGE-2 which, in
turn, prevents bacterial spread by infected cells and increased host
resistance toMtb infection. PGE-2 also was demonstrated to restore
control over Mtb infection in the absence of IL-1. In addition, IL-1
controls infection by negatively regulating type I interferon (IFN)
through PGE-2. Zileuton, a 5-LO inhibitor which inhibits type I IFN
expression through relative increases in PGE-2, also has beendemonstrated to confer protection against Mtb in mice in the
context of type I IFN mediated disease [6].
These ﬁndings suggest the possibility of host-directed therapy
of TB, explored by Mayer-Barber in a mouse model. As a host-
directed therapy, Zileuton may offer protection even after the
onset of TB disease. The ﬁndings also suggest a mechanism by
which viral infections such as inﬂuenza may increase susceptibility
to developing active TB disease, by increasing expression of type I
IFNs [7]. Mayer-Barber concluded by noting that further under-
standing the role of certain key cytokines in mediating Mtb-
induced pathogenesis may offer greater insights into optimizing
viral vector selection for TB vaccines and selecting appropriate
adjuvants to enhance TB vaccine effects.
4. Evaluation of lesions and encapsulation determine the
development of human pulmonary tuberculosis and supports
the need for experimental modeling in larger mammalian
models
Dr. Pere-Joan Cardona's (Institute Germans Trias i Pujol, Cata-
lonia, Spain) presentation focused upon the importance of using
larger animals to accurately model Mtb infection and disease. His
premise is based on the pulmonary pathology of TB disease in
humans, which classically includes exudative lesions as markers of
progression to disease. TB disease most commonly occurs in the
upper lobes of the lung, possibly due to less breathing amplitude,
that facilitates the local accumulation of bacilli and the attraction of
neutrophils; and a poorer encapsulation capacity [8,9]. According
to Cardona, encapsulated lesions such as those seen in primary
human TB can only be seen in larger animal models due to the
presence of substantial interlobular septae, not present in smaller
animal models such as the mouse, guinea pig, or even non-human
primates (NHPs) [10,11]. Thus, experimental modeling with small
animals can miss an essential protective reaction, the encapsula-
tion, that stops the progression of the lesions towards active dis-
ease. When infection occurs in humans, two different types of
lesions can be found in the same area: proliferative lesions,
resulting from low bacillary load and subsequently controlled
infection, and exudative lesions, representing sites of progression
to disease linked to high bacillary load. Eventually, bronchogenic
local coalescence, where daughter lesions occurring in a discrete,
peri-bronchial region area coalesce, lead to overt disease [9,12].
These destructive lesions have high numbers of neutrophils, lead-
ing to local dissemination. Circulating foamy macrophages con-
taining Mtb from both proliferative and exudative lesions may also
contribute to dissemination [13]. Cardona noted that in a mouse
model with the C3HeB/FeJ strain, ibuprofen was able to reduce the
propensity toward progression, likely by reducing IL-17 release
which has the effect of reducing the extent of inﬁltration by neu-
trophils [14]. He concluded by re-emphasizing the need to include
large animal species, like the mini-pig [15], among those utilized as
models of Mtb infection and TB disease in challenge experiments
designed to assess TB vaccine effectiveness.
5. Anti-TB immunity components and mechanisms in
primates
Dr. Zheng W. Chen (University of Illinois College of Medicine,
USA) discussed evidence of anti-Mtb immune components and
mechanisms relevant to TB vaccine development in non-human
primate (NHP) models. His lab has addressed the immune mecha-
nisms underlying CD4þ T-cell immunity against Mtb infection [16].
Although the role of CD8þ T-cells in anti-Mtb immunity is contro-
versial in mice, and no clear correlates of Th1 immune protection
against human Mtb have been demonstrated, Chen described work
L.K. Schrager et al. / Tuberculosis 99 (2016) S3eS7 S5in his lab demonstrating that CD8þ T-cells are critical for anti-Mtb
immunity [17] and that rapid clonal expansion and pulmonary
trafﬁcking/accumulation of antigen-speciﬁc CD8þ T-cells and CD4þ
Th1 cells contribute to protection [18]. The potential importance of
Th22 cells in anti-Mtb activities also was described [19].
Dr. Chen also summarized his laboratory's investigations eluci-
dating immune responses, functions and early anti-TB immunity
for phosphoantigen (pAg)-speciﬁc gd T-cells. A subset of gd T-cells
capable of recognizing TB pAg exist only in humans and NHPs. This
Vg2Vd2 T-cell subset predominantly constitutes 60e95% of total
human gd T-cells in circulation. The Vg2Vd2 T-cell subset can
mount clonal expansion/recall expansion with potent effector
functions, which correlate with detectable immunity to Mtb and
other infections [20e23]. Mechanistic studies using gd T-cell re-
ceptor tetramers and knock-out mutants of microbes demonstrate
that expansions and functions of Vg2Vd2 T-cell subset are driven by
gd TCR interaction with pAg (E)-4-hydroxy-3-methyl-but-2-enyl
pyrophosphate (HMBPP) instead of other host or microbial factors
[24,25]. Th17-related cytokines and IL-2 contribute to pAg expan-
sion and recall expansion of Vg2Vd2 T-cell subset during BCG
vaccination and Mtb infection [26,27]. Treatment of NHPs with
pAg/IL-2 during Mtb infection expands and differentiates the
Vg2Vd2 T-cell subset and induces immune resistance to TB, char-
acterized by smaller lesions and lower bacterial burden [28]. These
anti-Mtb effects are linked to the CTL killing of Mtb, production of
cytokines, and gd T-cell-driven enhancement of CD4þ T-cell and
CD8þ T-cell responses.
6. Lung resident and circulating pro-inﬂammatory MAIT cells
characterize pulmonary tuberculosis
Dr. David Lewinsohn (Oregon Health and Science University,
USA), noted that both extracellular and intracellular defense
mechanisms cooperate to control Mtb infection and disease.
Extracellular mechanisms include B-cell generated antibodies, a
combination of innate and antibody-associated immune re-
sponses occurring at mucosal surfaces, and an inﬂammatory
response resulting from neutrophil attraction. Components of the
intracellular immune response active against TB include CD4þ T-
cells, CD8þ T-cells and natural killer (NK) T-cells [29]. Lewinsohn
emphasized that CD8þ T-cell responses are critically important in
detecting and destroying Mtb-infected macrophages, dendritic
cells, and epithelial cells [30]. While many CD8þ T-cell responses
to Mtb infection are classically MHC-I restricted, Lewinsohn noted
that non-classical responses are common as well [31e33]. Non-
classical MHC restriction, evolved to present ligands not usually
seen in the human host, and can directly stimulate CD8þ T-cell
responses. Examples of non-classical MHC restriction that may
play a role in the control of TB include CD1 a-c, MR1 and HLA-E-
restricted responses [34].
Mucosa-associated, invariant T-cells (MAITs) represent a sub-
class of CD8þ T-cells activated via non-classical, MHC-related pro-
tein 1 (MR1) restriction. MR1 is encoded by a gene on chromosome
1 rather than chromosome 6 like MHC, and is the most conserved
class I molecule in mammals [35]. It binds small molecular me-
tabolites, such as vitamin metabolites. MAITs are capable of
recognizing epithelial cells as well as myeloid derived cells infected
with Mtb. Circulating MAIT cells are prevalent during latent TB
infection but are absent in the circulation during active TB infection
as they leave the circulation andmigrate to the site of Mtb infection
in the lung parenchyma [36]. MAIT enrichment has been demon-
strated in bronchoalveolar lavage ﬂuid obtained from patients with
active TB. Pathogen reactive MAITs have been isolated and most
have been found to be TRAV1-2 (T-cell receptor alpha) positive
although some are not. When queried whether MAITs havememory, Lewinsohn noted that the diversity of T-cell receptor us-
age seen in MAITs, a factor that correlates with responses to
different organisms via discrete ligands, suggests that MAITs are
capable of immunological memory.7. COX inhibitors downregulate tregs in tuberculosis: a
potential adjuvant for vaccine
Prof. Anne Margarita Dyrhol-Riise (Oslo University Hospital,
Norway) emphasized the need to develop host-directed therapies
for TB disease. To this end, she addressed the role of
cyclooxygenase-2 (COX-2) during TB infection and described the
potential use of COX-2 inhibitors both as adjuvants for TB vaccines
and as a component of a putative host-directed treatment for TB
disease. Increases in COX-2 leads to production of prostaglandin-2
(PGE-2) and suppression of T-cell immune responses by a COX-2-
PGE(2)-dependent mechanism that may enhance TB disease pro-
gression. COX-2 can be induced in vitro by the TB virulence factor
ESAT-6 during TB infection in persons with both active TB disease
and latent Mtb infection. In particular, high levels of COX-2 are
found in monocytes obtained from patients with active TB. Further,
COX-inhibitors down-regulate the fraction ofMtb speciﬁc FOXP3þ T
regulatory cells (Treg) [personal communication]. Dyrhol-Riise
suggested that therapeutic vaccination, coupled with COX-2
dependent immunomodulation, could represent an improved
strategy for vaccination against tuberculosis, because COX-2 in-
hibitors could potentiate vaccine efﬁciency against TB by down-
regulating both PGE-2 production and Treg activity.8. Searching for the mechanism of protection and
attenuation of MTBVAC
MTBVAC is an attenuated strain of Mtb, resulting frommutations
in the phoP and fadD26 genes. Dr. Carlos Martin (University of Zar-
agoza, Spain) explained that genomic comparative studies have
shown loss of a number of major mycobacterial antigens and more
than 20% of Mtb-speciﬁc human T-cell epitopes in BCG relative to
pathogenic Mtb. The phoP and fadD26 stable deletions in MTBVAC
prevent secretion of ESAT6 and the production of themajor virulence
lipid phthiocerol dimycocerosate (PDIM), rendering the mutant
attenuated [37]. The phoPmutation also results in the inability ofMtb
to synthesize trehalose-derived lipids such as diacyltrehaloses (DAT)
and polyacyltrehaloses (PAT), along with the increased secretion of
major antigens suchasAg85 complex [38,39].MTBVACdemonstrates
protection from Mtb challenge in different animal models which is
signiﬁcantly better than that induced by BCG.
MTBVAC represents theﬁrst live, attenuated,Mtb-derived vaccine
that has advanced to clinical trials. Importantly, MTBVAC has
demonstrated comparable safety to BCG in these trials thus far. An
early phase 1a study ofMTBVAC in Switzerland demonstrated a good
safety proﬁlewith no severe adverse events (SAEs) [40]. As a result of
the satisfactory safety proﬁle and encouraging immunogenicity re-
sults demonstrated in thisphase1 study, further clinicaldevelopment
in different target populations in high burden countries is planned,
beginning with a phase 1b study in newborns already initiated in
Cape Town by the South African Tuberculosis Vaccine Initiative
(SATVI). Martin noted that as MTBVAC clinical studies progress to-
ward efﬁcacy assessments, it will be important to evaluate the po-
tential effect that previous BCG vaccination, environmental
mycobacteria, orMtbexposuremighthave inmaskingorblocking the
effect of the vaccine. Ultimately, MTBVAC efﬁcacy studies in both
neonates without previous exposure to environmental mycobacteria
or BCG vaccination, and in adults, are anticipated.
L.K. Schrager et al. / Tuberculosis 99 (2016) S3eS7S69. H1/IC31- vaccine induced long term CD4-memory
responses in HIV infected volunteers correlate with antiviral
innate immune activation
Dr. Claudia Daubenberger (Swiss Tropical and Public Health
Institute, Switzerland) described an immunogenicity and safety
study of the H1/IC31 protein-adjuvant vaccine in healthy, Tanza-
nian HIV-infected persons with CD4þ lymphocyte counts of
>350 cells/mm3 and latent TB infection. Volunteers were not under
retroviral treatment at time of vaccination and H1/IC31 was
administered twice (day 0 and day 56). Peripheral blood mono-
nuclear cells were collected at days 0, 14, 56, 70 and 182 for
immunogenicity analysis. Enhanced poly-functional CD4þ T-cell
responses in both central and effector memory CD4þ T-cells were
observed secreting IFN-g, TNFa and IL-2. Overall this vaccine was
well-tolerated in HIV positive individuals with immune responses
highest at day 70 and still detected at day 182. Next, high inter-
mediate and non-responders based on detection of cytokine
expressing central and effector memory CD4þ T-cells 182 days after
ﬁrst immunization were identiﬁed [41]. Amplicon-based transcript
quantiﬁcation using next-generation sequencing was performed on
whole blood samples collected on days 0 and 3 to identify differ-
entially expressed genes that correlated with maintenance of
vaccine-induced immune responses at day 182. Volunteers with
higher expression levels of genes involved in anti-viral innate im-
munity at baseline showed impaired vaccine-speciﬁc central and
effector memory maintenance 182 days after vaccination. Toll-like
receptor-8 single nucleotide polymorphism homozygotes (SNP
rs3764880) had lower expressed anti-viral response genes, which
provided a higher chance of maintaining a better vaccine response.
In summary, in HIV-infected volunteers, expression levels of genes
involved in the anti-viral innate immune response at study baseline
affected long-term maintenance of H1/IC31 vaccine-induced
cellular immunity [41].
10. Conclusion
The fundamental strategy underpinning Mtb subunit vaccine
development is to identify the pathogen-derived antigens needed
to elicit a protective immune response against the pathogen and
incorporate these antigens in a vaccine. Currently, both critical
components of this strategy e the identiﬁcation of necessary
antigens and the elucidation of a protective immune response e
are lacking with respect to Mtb infection and TB disease. Progress
is being made, however, on both fronts. Intensive studies have
now identiﬁed hundreds of TB antigens, with active assessments
of the tens of thousands of predicted epitopes underway. Such
assessments have called into question the basic tenet of past an-
tigen discovery efforts that immunodominant antigens are the
most likely to generate protective immune responses. Their highly
conserved nature has prompted a reassessment of a narrow focus
on such antigens and has stimulated a broadening of interest
beyond classical immunodominant antigens to other antigens
that may play an equal or greater role in immune-mediated
protection.
A similar broadening of interest is occurring among in-
vestigators assessing immune correlates of protection against TB.
The historical focus on classical CD4þ and CD8þ T-cell responses is
being extended to consider the potentially critical roles that non-
classical immune responses, such as those mediated by lung resi-
dent MAIT cells, gd T-cells, antibodies, and by related responses
such as ADCC, may play in protecting against Mtb infection and TB
disease. Furthermore unbiased transcriptomic -and other omic-
studies are being used increasingly to characterize vaccine
induced responses in TB. Taken together, these new considerationsregarding antigen selection and correlates of immunity increase the
likelihood of an important diversiﬁcation in the TB vaccine candi-
dates we are likely to see in the future, increasing the chances of TB
vaccine success.
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